John Kendrick, MD
Surgery · Springdale, ARNPI 1902812019
Payments from drug & device makers
Across 79 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$285
- AstraZeneca$238
- GSK$195
- Novo Nordisk$80
- AbbVie$71
- Eisai Inc.$69
- plus $574 from 22 others
What the payments were for
- Food & beverage$1,47798%
- Education$352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 9 | $285 |
| AstraZeneca | 8 | $238 |
| GSK | 13 | $195 |
| Novo Nordisk | 5 | $80 |
| AbbVie | 4 | $71 |
| Eisai Inc. | 5 | $69 |
| Merck | 2 | $47 |
| Pfizer | 3 | $44 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 3 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Novartis | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Mylan Specialty L.p. | 2 | $29 |
| Boehringer Ingelheim | 2 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Biogen | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Zimmer Biomet | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Indivior Inc. | 1 | $15 |
| Biocompatibles, Inc. | 1 | $15 |
| Bioventus LLC | 1 | $15 |
| Vertex | 1 | $15 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$1,512 in reported general payments places this provider in the 45th percentile of 227 surgery providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 138 | $131,610 |
| EliquisApixaban | 227 | $120,980 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $86,808 |
| TrulicityDulaglutide | 61 | $78,974 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,966 | $72,386 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 75 | $56,355 |
| XareltoRivaroxaban | 79 | $53,198 |
| MovantikNaloxegol Oxalate | 98 | $32,746 |
| JardianceEmpagliflozin | 38 | $31,828 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 810 | $31,700 |
| BelbucaBuprenorphine Hcl | 33 | $31,227 |
| Oxycodone Hcl | 1,363 | $26,279 |
| Xtampza ErOxycodone Myristate | 45 | $25,084 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 109 | $23,830 |
| JanuviaSitagliptin Phosphate | 20 | $23,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica, Premarin | $44 | $148,033274 claims |
| Novo NordiskOzempic | $80 | $131,610138 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta | $238 | $90,979168 claims |
| GSKTrelegy Ellipta | $195 | $86,808111 claims |
| Lilly USA, LLCTrulicity | $33 | $78,97461 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $41 | $56,31278 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Buprenorphine Hcl | $35 | $46,014372 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $24 | $40,50756 claims |
| AbbVieLinzess, Creon | $71 | $29,61547 claims |
| MerckJanuvia | $47 | $23,47020 claims |
| NovartisEntresto | $32 | $16,61026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 227 surgery providers in Arkansas.
Other surgery in Springdale
- Kyle KalkwarfLittle Rock$573K
- Joshua RollerFayetteville$248K
- Alice CherquiJonesboro$71K
- Brian PottorfFayetteville$64K
- Samuel BledsoeLittle Rock$53K
- Danny ListerHeber Springs$48K
- Michael PollockLittle Rock$45K
- James WalkerLittle Rock$41K
- Jessica HobbyJonesboro$40K
- Whitney DavidsonRogers$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.